UZH-Logo

Maintenance Infos

Browse by Creators - Zurich Open Repository and Archive

Navigate back| Up a level
Export as
Number of items: 9.

Wick, W; Roth, P; Hartmann, C; Hau, P; Nakamura, M; Stockhammer, F; Sabel, M C; Wick, A; Koeppen, S; Ketter, R; Vajkoczy, P; Eyupoglu, I; Kalff, R; Pietsch, T; Happold, C; Galldiks, N; Schmidt-Graf, F; Bamberg, M; Reifenberger, G; Platten, M; von Deimling, A; Meisner, C; Wiestler, B; Weller, M (2016). Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. Neuro-Oncology, 18(11):1529-1537.

Weller, Michael; Tabatabai, G; Kästner, B; Felsberg, J; Steinbach, J P; Wick, A; Schnell, O; Hau, P; Herrlinger, U; Sabel, M C; Wirsching, H G; Ketter, R; Bähr, O; Platten, M; Tonn, J C; Schlegel, U; Marosi, C; Goldbrunner, R; Stupp, R; Homicsko, K; Pichler, J; Nikkhah, G; Meixensberger, J; Vajkoczy, P; Kollias, S; Hüsing, J; Reifenberger, G; Wick, W (2015). MGMT Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. Clinical Cancer Research, 21(9):2057-2064.

Eisele, G; Wick, A; Eisele, A C; Clément, P M; Tonn, J; Tabatabai, G; Ochsenbein, A; Schlegel, U; Neyns, B; Krex, D; Simon, M; Nikkhah, G; Picard, M; Stupp, R; Wick, W; Weller, M (2014). Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 117(1):141-145.

Seystahl, K; Wiestler, B; Hundsberger, T; Happold, C; Wick, W; Weller, M; Wick, A (2013). Bevacizumab Alone or in Combination with Irinotecan in Recurrent WHO Grade II and Grade III Gliomas. European Neurology, 69(2):95-101.

Wick, A; Dörner, N; Schäfer, N; Hofer, S; Heiland, S; Schemmer, D; Platten, M; Weller, M; Bendszus, M; Wick, W (2011). Bevacizumab does not increase the risk of remote relapse in malignant glioma. Annals of Neurology, 69(3):586-592.

Wick, W; Wick, A; Weiler, M; Weller, M (2011). Patterns of progression in malignant glioma following anti-VEGF therapy: perceptions and evidence. Current Neurology and Neuroscience Reports, 11(3):305-312.

Wick, W; Roth, P; Wick, A; Weller, M (2010). Was gibt es Neues in der Neuroonkologie. Aktuelle Neurologie, 37(9):454-460.

Wick, A; Pascher, C; Wick, W; Jauch, T; Weller, M; Bogdahn, U; Hau, P (2009). Rechallenge with temozolomide in patients with recurrent gliomas. Journal of Neurology, 256(5):734-741.

Wick, W; Stupp, P; Beule, A C; Bromberg, J; Wick, A; Ernemann, U; Platten, M; Marosi, C; Mason, W P; van den Bent, M; Weller, M; Rorden, C; Karnath, H O (2008). A novel tool to analyze MRI recurrence patterns in glioblastoma. Neuro-Oncology, 10(6):1019-1024.

This list was generated on Thu Jul 27 03:49:46 2017 CEST.